Related Experiment Video
Updated: Apr 18, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
Published on: May 26, 2017
Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2
Li Ren1, Jonas Grina, David Moreno
1Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States.
Abstract:
Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.
More Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
09:58An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
Published on: May 2, 2025
Related Concept Videos
MAPK Signaling Cascades
Mitogens and the Cell Cycle
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...